| Přispěvatelé: |
Bosch, J.L.H.R., Barentsz, J.O., van Melick, H.H.E., Somford, D.M., University Utrecht |
| Popis: |
Part III: Outcomes of the FUTURE trial In chapter 5 the primary outcomes of the FUTURE trial are presented. Among the 665 recruited patients, 234 (35%) had PIRADS≥3 lesions on mpMRI and were randomised for subsequent mpMRI based TB (79 for FUS-TB, 78 for COG-TB, and 77 for MRI-TB). There were no significant differences in baseline characteristics or mpMRI outcomes among the groups. Overall 115 cases of prostate cancer (49%) and 78 cases of clinically significant prostate cancer (33%) (Gleason score ≥3+4 (ISUP grade ≥2)) cases were detected using TB. We demonstrated that there are no statistically significant differences in the overall detection rates of prostate cancer among three techniques of mpMRI based TB (FUS-TB 49%, COG-TB 44%, MRI-TB 55%, p=0.4). Furthermore, no significant differences have been found in the detection rates of clinically significant prostate cancer among the techniques (FUS-TB 34%, COG-TB 33%, MRI-TB 33%, p>0.9). Finally, pre-specified sub-analysis did not demonstrate statistically significant differences in (clinically significant) prostate cancer detection rates between the techniques in various subgroups of patients. The study was, however, hampered by a lower yield of PIRADS≥3 on mpMRI than predicted and thus low availability of TB, causing under-powering for the primary endpoint. Thus, these results should be considered with caution. Chapter 6 presents a secondary analysis of the FUTURE trial, in which the yield of mpMRI based TB was compared with the yield of repeated TRUS-SB. In a FUTURE trial cohort of 152 patients that underwent both TB and SB, we demonstrated that TB detected significantly more prostate cancer than SB (47% vs 32%, p |
